STOCK TITAN
  1. Home
  2. News
  3. DXCM

Dexcom Inc - DXCM STOCK NEWS

Welcome to our dedicated news page for Dexcom (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dexcom's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dexcom's position in the market.

News
Dexcom Publishes Annual Sustainability Report
Rhea-AI Summary
DexCom, Inc. releases its annual Sustainability Report, showcasing advancements in corporate sustainability disclosures, including expanded greenhouse gas emissions data and increased transparency in pay-equity practices. The report highlights key initiatives aligned with Dexcom's core values and business strategy, emphasizing its commitment to stakeholders and global health through access to CGM technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none
-
News
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
Rhea-AI Summary
DexCom, Inc. (DXCM) plans to release its first quarter 2024 financial results on April 25, 2024. A conference call will be held to review the performance, starting at 4:30 p.m. (Eastern Time) on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
earnings
-
News
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
Rhea-AI Summary
DexCom, Inc. (NASDAQ:DXCM) announces FDA clearance for Stelo, the first glucose biosensor in the US that doesn't require a prescription. Stelo, a small wearable sensor worn on the back of the upper arm, will provide glucose insights directly to a user's smartphone. Created by the makers of Dexcom G7, Stelo aims to empower people with Type 2 diabetes not using insulin to take control of their health. Available summer 2024, Stelo will cater to the approximately 25 million people in the US living with Type 2 diabetes who do not use insulin and can benefit from continuous glucose monitoring technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
none
News
Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
Rhea-AI Summary
DexCom, Inc. announced new clinical evidence supporting the use of continuous glucose monitoring (CGM) for automated insulin delivery systems, showcasing benefits for Type 2 diabetes management and reduced mortality in Type 1 and Type 2 diabetes. The company launched G7 in 16 new markets and Dexcom ONE+ in eight markets, with 'Direct-to-watch' functionality for Apple Watch. Dexcom's AID systems, in partnership with Tandem and Insulet, demonstrated significant health outcomes with low event rates of severe hypoglycaemia and diabetic ketoacidosis. Clinical studies also highlighted the effectiveness of CGM in improving HbA1c and glucose range for Type 2 diabetes. Dexcom continues to innovate and expand access to its CGM technology globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
News
Dexcom Announces Upcoming Conference Presentation
Rhea-AI Summary
DexCom, Inc. (DXCM) will present an update at the 45th Annual Raymond James Institutional Investors Conference. The live presentation by Sean Christensen, VP of Finance and Investor Relations, will be webcasted on March 5th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
conferences
-
News
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Rhea-AI Summary
DexCom, Inc. (Nasdaq: DXCM) reported strong financial results for the fourth quarter and fiscal year ended December 31, 2023. Revenue grew 27% to $1.03 billion in the fourth quarter and 24% to $3.62 billion for the full year. The company also achieved significant operating income and net income growth. Strategic highlights include the submission of Dexcom's new glucose sensor for people with type 2 diabetes to the FDA for review and partnerships with Tandem Diabetes Care and Beta Bionics for insulin pump connectivity. The company has reiterated its fiscal year 2024 guidance with expected revenue of approximately $4.15 - 4.35 billion and non-GAAP operating margin of approximately 20%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.18%
Tags
earnings
News
Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People
Rhea-AI Summary
Dexcom, Inc. (Nasdaq: DXCM) has launched its latest continuous glucose monitoring (CGM) system, Dexcom ONE+, in Spain, Belgium, and Poland, with the Netherlands launching next week. The system is designed to make it easier for people with Type 1 and Type 2 diabetes to manage their condition and see their glucose readings without painful fingerpricks. Dexcom ONE+ incorporates user and healthcare professional feedback, offering personalization, flexibility, and the highest waterproof rating when compared to other CGM brands.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
none
-
News
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time
Rhea-AI Summary
DexCom, Inc. (DXCM) plans to release its Q4 and FY 2023 financial results on February 8, 2024, followed by a conference call to review performance. The call will be webcast and archived on the investor relations website. Dial-in details are provided for listening to the conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
earnings
-
News
Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland
Rhea-AI Summary
Dexcom, Inc. (Nasdaq: DXCM) has broken ground on its new state-of-the-art manufacturing facility in Athenry, Co. Galway, creating over 1,000 jobs and representing one of the biggest single private sector investments in the West of Ireland. The facility will produce millions of Dexcom rtCGM sensors annually, helping improve the lives of people with diabetes in EMEA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
News
A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2
Rhea-AI Summary
Dexcom, Inc. (Nasdaq: DXCM) has announced the launch of the Dexcom G7 Continuous Glucose Monitoring (CGM) System, which now connects with the t:slim X2 insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa. The system combines the power and accuracy of Dexcom G7 with the discretion of the Tandem t:slim X2. Dexcom is recognized as the most clinically studied CGM brand with AID capabilities, with more than 1 million patient years of cumulative use. New results from the COMISAIR seven-year follow up show significant and continued reduction of HbA1c as well as a lower risk of the development or progression of diabetic retinopathy associated with the use of real-time CGM by people with Type 1 diabetes. Dexcom G7 is the fastest CGM connected to the t:slim X2 insulin pump, with a 30-minute sensor warmup time, and offers industry-leading remote monitoring capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock DXCM logo
Dexcom Inc

Nasdaq:DXCM

DXCM Rankings

#230 Ranked by Market Cap
#3663 Ranked by Stock Gains
N/A Ranked by Dividends

DXCM Stock Data

52.48B
379.71M
0.41%
103.06%
3.78%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Diego

About DXCM

founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.